When to Order Imaging for Nonischemic Myocardial Disease with Clinical Manifestations (Ischemic Cardiomyopathy Already Excluded): ACR Appropriateness Decoded

When to Order Imaging for Nonischemic Myocardial Disease with Clinical Manifestations (Ischemic Cardiomyopathy Already Excluded): ACR Appropriateness Decoded

You are evaluating a patient with signs of heart failure—dyspnea, fatigue, and peripheral edema. Their initial workup has confidently excluded ischemic cardiomyopathy, but the underlying cause of their myocardial disease remains unclear. The differential is broad, including hypertrophic, restrictive, inflammatory, or arrhythmogenic cardiomyopathies. Choosing the next imaging study is critical for diagnosis, prognosis, and guiding therapy, but the options can be overwhelming. An incorrect or delayed choice can lead to diagnostic uncertainty and suboptimal patient care. This guide provides a clear, scannable summary of the American College of Radiology (ACR) Appropriateness Criteria to help you select the right imaging test for patients with suspected nonischemic myocardial disease.

What Does ACR Nonischemic Myocardial Disease with Clinical Manifestations (Ischemic Cardiomyopathy Already Excluded) Cover?

This ACR topic provides imaging recommendations for adult and pediatric patients who present with clinical signs or symptoms suggestive of myocardial disease where coronary artery disease has already been reasonably ruled out as the primary cause. The guidelines are structured around the suspected underlying etiology based on the clinical presentation, helping to differentiate between various forms of nonischemic cardiomyopathy.

The criteria specifically address initial imaging for several key clinical scenarios:

• Suspected hypertrophic cardiomyopathy (HCM)
• Suspected restrictive cardiomyopathy or infiltrative disease (e.g., amyloidosis, sarcoidosis)
• Suspected nonischemic dilated and unclassified cardiomyopathy
• Suspected arrhythmogenic cardiomyopathy, often presenting with ventricular arrhythmias
• Suspected inflammatory cardiomyopathy (myocarditis)

These guidelines do not apply to the initial workup of suspected ischemic heart disease, acute coronary syndrome, or for routine surveillance of known cardiomyopathy. The core assumption is that ischemia has been excluded by prior testing or is considered highly unlikely based on the clinical context.

What Imaging Should I Order for Nonischemic Myocardial Disease with Clinical Manifestations (Ischemic Cardiomyopathy Already Excluded)? Recommendations by Clinical Scenario

The ACR recommendations prioritize non-invasive imaging, with transthoracic echocardiography (TTE) and cardiac magnetic resonance (CMR) imaging serving as the cornerstones of evaluation. The choice depends on the specific suspected diagnosis.

For initial imaging in a patient with suspected hypertrophic cardiomyopathy, both resting transthoracic echocardiography and cardiac MRI (with or without IV contrast) are rated Usually appropriate. TTE is an excellent first-line modality to assess for asymmetric septal hypertrophy and systolic anterior motion of the mitral valve. CMR offers superior tissue characterization, allowing for the detection of myocardial fibrosis with late gadolinium enhancement (LGE), a key prognostic marker. Stress echocardiography May be appropriate to evaluate for dynamic outflow tract obstruction.

When the clinical picture suggests restrictive cardiomyopathy or infiltrative disease, the recommendations are similar. Resting TTE and cardiac MRI with IV contrast are Usually appropriate. TTE can reveal biatrial enlargement and diastolic dysfunction, while CMR is highly sensitive for specific LGE patterns characteristic of diseases like cardiac amyloidosis or sarcoidosis. In this context, FDG-PET/CT heart imaging May be appropriate, particularly for assessing active inflammation in cardiac sarcoidosis.

In cases of suspected nonischemic dilated and unclassified cardiomyopathy or suspected arrhythmogenic cardiomyopathy, the guidance is consistent. Resting TTE and cardiac MRI (with or without contrast) are Usually appropriate. TTE provides essential information on ventricular size and global systolic function. CMR is invaluable for detecting the fibrofatty infiltration characteristic of arrhythmogenic right ventricular cardiomyopathy (ARVC) and identifying other structural abnormalities or scar patterns that could be an arrhythmogenic substrate.

For suspected inflammatory cardiomyopathy (myocarditis), resting TTE and cardiac MRI with IV contrast are again rated Usually appropriate. TTE can show ventricular dysfunction and wall motion abnormalities. However, CMR is the premier non-invasive tool for diagnosing myocarditis, using specific sequences (T2-weighted imaging for edema, LGE for necrosis and fibrosis) to confirm inflammation. FDG-PET/CT heart imaging May be appropriate for evaluating ongoing inflammatory activity, especially in giant cell myocarditis or sarcoidosis.

ACR Imaging Recommendations Table

Adult vs. Pediatric Nonischemic Myocardial Disease with Clinical Manifestations (Ischemic Cardiomyopathy Already Excluded) Imaging: Radiation Dose Tradeoffs

A key advantage of the primary recommended modalities for nonischemic cardiomyopathy—echocardiography and cardiac MRI—is the complete absence of ionizing radiation. This makes them exceptionally safe for all patient populations, including children, young adults, and patients who may require serial imaging over their lifetime. The ACR designates both with a relative radiation level (RRL) of “O 0 mSv.”

Modalities involving ionizing radiation, such as cardiac CT and FDG-PET/CT, are generally rated as May be appropriate or Usually not appropriate for the initial evaluation in these scenarios. When these studies are considered, radiation dose becomes a critical factor, especially in pediatric patients. The ACR guidelines reflect this by providing distinct pediatric RRLs that are often in a lower effective dose range than their adult counterparts (e.g., 3-10 mSv for a pediatric cardiac CT vs. 10-30 mSv for an adult). This difference underscores the principle of As Low As Reasonably Achievable (ALARA) and the importance of tailoring imaging protocols to minimize cumulative radiation exposure in younger patients, whose tissues are more radiosensitive and who have a longer lifespan over which potential stochastic effects could manifest.

Imaging Protocol Details for Nonischemic Myocardial Disease with Clinical Manifestations (Ischemic Cardiomyopathy Already Excluded)

Once you have decided on the right study, the specific imaging protocol is crucial for obtaining diagnostic-quality images. The value of a cardiac MRI, for instance, depends heavily on the correct sequences, contrast timing, and patient preparation. Standardized, evidence-based protocols ensure that the examination effectively answers the clinical question, preventing the need for repeat or alternative studies. While this article summarizes which study to order, detailed procedural guides are essential for execution. Our library contains technical specifications for many common imaging procedures, designed to help technologists and radiologists perform studies consistently and effectively.

Tools to Help You Order the Right Study

Navigating imaging guidelines during a busy clinical shift can be challenging. To streamline the process of ordering the correct study and managing patient care, several digital tools can provide immediate support.

• ACR Appropriateness Criteria Lookup: For clinical scenarios beyond nonischemic myocardial disease, this tool provides direct access to the full ACR guidelines, helping you find evidence-based recommendations for hundreds of clinical variants quickly and efficiently.

• Imaging Protocol Library: After choosing a study like cardiac MRI, you can use this library to find detailed, step-by-step protocols. This ensures the exam is technically optimized to provide the diagnostic information you need.

• Radiation Dose Calculator: When considering CT or PET scans, this tool helps estimate cumulative radiation exposure for your patients. It is an invaluable aid for informed decision-making and for communicating radiation risks and benefits to patients and their families.

Frequently Asked Questions about Imaging for Nonischemic Myocardial Disease

Why is transthoracic echocardiography (TTE) almost always a ‘Usually Appropriate’ first step?

Transthoracic echocardiography is non-invasive, widely available, cost-effective, and uses no ionizing radiation. It provides a wealth of information about cardiac structure and function, including ventricular size, wall thickness, ejection fraction, and valvular function. This makes it an ideal initial imaging test to narrow the differential diagnosis in suspected nonischemic cardiomyopathy and guide whether more advanced imaging is necessary.

In what scenarios is cardiac MRI (CMR) more valuable than echocardiography?

Cardiac MRI is superior to echocardiography for tissue characterization. It is particularly valuable when an infiltrative process (like amyloidosis or sarcoidosis), inflammatory process (myocarditis), or arrhythmogenic cardiomyopathy is suspected. The use of late gadolinium enhancement (LGE) allows CMR to identify and quantify myocardial fibrosis and scar, which has significant diagnostic and prognostic implications that cannot be assessed by echo.

Why is coronary angiography ‘Usually Not Appropriate’ for this clinical topic?

The premise of this ACR topic is that ischemic cardiomyopathy has already been reasonably excluded. Invasive coronary angiography is the gold standard for identifying obstructive coronary artery disease, but it carries procedural risks and radiation exposure. Since ischemia is not the primary concern in these defined scenarios, the risks of an invasive procedure generally outweigh the benefits, and non-invasive options are preferred.

What is the specific role of FDG-PET/CT in nonischemic cardiomyopathy?

FDG-PET/CT is rated as ‘May be appropriate’ for suspected restrictive/infiltrative and inflammatory cardiomyopathies. Its primary role is to detect active inflammation, as seen in conditions like cardiac sarcoidosis or giant cell myocarditis. In these diseases, identifying active inflammation can guide immunosuppressive therapy. It is not a first-line tool for all nonischemic cardiomyopathies but is reserved for specific clinical questions about inflammatory activity.

When might a cardiac CT be considered?

Cardiac CT is rated ‘May be appropriate’ across most variants. While not a primary diagnostic tool for myocardial tissue characterization compared to MRI, it can be a valuable alternative in patients with contraindications to MRI (e.g., certain implanted devices, severe claustrophobia). It provides excellent anatomic detail of cardiac and paracardiac structures and can be used to assess cardiac function, though it involves significant radiation exposure.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026